a Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology , University College London , London , UK.
b School of Engineering and Materials Science , Queen Mary University of London , London , UK.
Drug Deliv. 2018 Nov;25(1):435-447. doi: 10.1080/10717544.2018.1431981.
Persistent pain remains a major health issue: common treatments relying on either repeated local injections or systemic drug administration are prone to concomitant side-effects. It is thought that an alternative could be a multifunctional cargo system to deliver medicine to the target site and release it over a prolonged time window. We nano-engineered microcapsules equipped with adjustable cargo release properties and encapsulated the sodium-channel blocker QX-314 using the layer-by-layer (LbL) technology. First, we employed single-cell electrophysiology to establish in vitro that microcapsule application can dampen neuronal excitability in a controlled fashion. Secondly, we used two-photon excitation imaging to monitor and adjust long-lasting release of encapsulated cargo in target tissue in situ. Finally, we explored an established peripheral inflammation model in rodents to find that a single local injection of QX-314-containing microcapsules could provide robust pain relief lasting for over a week. This was accompanied by a recovery of the locomotive deficit and the amelioration of anxiety in animals with persistent inflammation. Post hoc immunohistology confirmed biodegradation of microcapsules over a period of several weeks. The overall remedial effect lasted 10-20 times longer than that of a single focal drug injection. It depended on the QX-314 encapsulation levels, involved TRPV1-channel-dependent cell permeability of QX-314, and showed no detectable side-effects. Our data suggest that nano-engineered encapsulation provides local drug delivery suitable for prolonged pain relief, which could be highly advantageous compared to existing treatments.
常见的治疗方法依赖于局部重复注射或全身药物治疗,容易产生伴随的副作用。人们认为,一种替代方法可能是一种多功能货物系统,将药物输送到靶位并在较长的时间窗口内释放。我们纳米工程化了微胶囊,这些微胶囊具有可调节的货物释放特性,并使用层层(LbL)技术封装了钠离子通道阻滞剂 QX-314。首先,我们采用单细胞电生理学在体外建立了这样一种机制,即微胶囊的应用可以以可控的方式抑制神经元的兴奋性。其次,我们使用双光子激发成像来监测和调节目标组织中包裹货物的长效释放。最后,我们在啮齿动物中探索了一种已建立的外周炎症模型,发现单次局部注射含有 QX-314 的微胶囊可以提供长达一周以上的强烈止痛效果。这伴随着运动障碍的恢复和持续性炎症动物焦虑的改善。事后免疫组织化学证实微胶囊在数周内逐渐降解。整体治疗效果持续时间比单次局灶性药物注射长 10-20 倍。它取决于 QX-314 的包封水平,涉及 TRPV1 通道依赖性 QX-314 的细胞通透性,并且没有检测到可察觉的副作用。我们的数据表明,纳米工程化封装提供了适合长期缓解疼痛的局部药物递送,与现有治疗方法相比具有很大的优势。